Zacks Investment Research upgraded shares of NUVASIVE INC (NUVA) from NEUTRAL to OUTPERFORM on January 16, 2013, with a target price of $18.80.
NUVASIVE is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on NUVASIVE INC (NUVA),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment